BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $10.91B
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): 16.8
• Beta (1Y): 0.44
• Revenue Growth: 17.38%
• EPS Growth: 153.58%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 1.23
• Shares Outstanding: 192,014,600
• 10 Day Avg. Volume: 3,281,269
• 30 Day Avg. Volume: 2,238,064
• PEG Ratio: 0.21
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 4.38
• P/FCF Ratio: 26.27
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 3.28
• Enterprise Value/Gross Profit: 4.12
• Enterprise Value/Ebitda: 11.35
• 1Y Price Target: $98.77
• Price Target Upside: 73.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 24

• Rating: 76 Outperform
• Price Target: $65.00 ▲(14.32% Upside)

BioMarin Pharmaceutical's overall stock score reflects strong financial performance and positive strategic developments, particularly in revenue growth and product expansion. The earnings call provided a positive outlook, although operational challenges and technical indicators suggest caution. The company's valuation is reasonable, supporting a solid investment case.

Positive Factors

Financial Performance

BMRN reported higher than expected second quarter total sales of $825M, an 11% QoQ increase.

Product Development

BMRN announced positive PK data from the ongoing Ph1 study of BMN 333 in healthy volunteers, which management believes translates into added growth in achondroplasia, strengthening BMRN's lead position in skeletal indications.

Profitability

The company updated its non-GAAP operating margin guidance from 32%–33% to 33%–34%, reflecting improved profitability expectations.

Negative Factors

Competition

Impending Voxzogo competition is expected by year-end, which could impact its market position.

Investor Sentiment

There are overly bearish expectations around the medium/long-term outlook for Voxzogo, which may affect investor sentiment.

Patent Issues

The EU patent Board's preliminary decision suggests that a BioMarin patent lacks disclosure needed to differentiate from prior art.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

How the Company Makes Money

BioMarin generates revenue primarily through the sale of its pharmaceutical products, which are targeted at rare diseases. Key revenue streams include the sale of its approved therapies, such as Vimizim (elosulfase alfa), Brineura (cerliponase alfa), and Kuvan (sapropterin dihydrochloride). Additionally, the company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to enhance its research capabilities and expand its market reach. These partnerships may involve co-development agreements, licensing fees, and milestone payments that contribute to BioMarin's earnings. The company's focus on rare diseases often allows it to command higher prices for its specialized treatments, further bolstering its revenue.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin Pharmaceutical demonstrates a robust financial trajectory with strong revenue growth from $2.09 billion in 2022 to $2.93 billion TTM, improved net profit and EBIT margins, and healthy free cash flow dynamics. The balance sheet is strong with low debt levels, ensuring financial stability.

Income Statement

BioMarin Pharmaceutical has demonstrated a robust financial performance with strong revenue growth, rising from $2.09 billion in 2022 to $2.93 billion TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, supported by efficient cost management. The net profit margin and EBIT margins have also shown significant improvement, indicating enhanced profitability. The consistent EBITDA margin growth highlights operational efficiency gains.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio, suggesting prudent financial leverage. The equity ratio is impressive, indicating a high level of asset financing through equity. The return on equity has improved substantially, showcasing the company's ability to generate profits from shareholders' investments. However, the company should continue monitoring its debt levels to maintain financial flexibility.

Cash Flow

BioMarin Pharmaceutical has demonstrated strong cash flow dynamics with significant growth in free cash flow, reflecting effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating robust cash generation capabilities. The improved free cash flow to net income ratio further underscores the company's solid cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.05B	2.85B	2.42B	2.10B	1.85B	1.86B
Gross Profit	2.43B	2.27B	1.84B	1.61B	1.38B	1.34B
EBITDA	882.65M	650.86M	310.28M	267.51M	48.03M	-5.85M
Net Income	657.24M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet
Total Assets	7.46B	6.99B	6.84B	6.38B	6.00B	5.85B
Cash, Cash Equivalents and Short-Term Investments	1.43B	1.14B	1.07B	1.29B	1.01B	1.07B
Total Debt	596.16M	602.71M	1.10B	1.08B	1.08B	1.08B
Total Liabilities	1.43B	1.33B	1.89B	1.77B	1.73B	1.74B
Stockholders Equity	6.03B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow
Free Cash Flow	691.43M	475.42M	51.65M	44.36M	185.31M	-52.15M
Operating Cash Flow	766.77M	572.84M	159.26M	175.90M	304.54M	85.36M
Investing Cash Flow	19.42M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
Financing Cash Flow	-539.65M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 56.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Negative. The current price of 56.86 is below the 20-day moving average (MA) of 58.64, below the 50-day MA of 57.32, and below the 200-day MA of 63.04, indicating a bearish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 44.02 is Neutral, neither overbought nor oversold. The STOCH value of 8.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	84 Outperform	$13.00B	10.44	26.08%	―	23.25%	64.46%
UTHR	80 Outperform	$13.64B	11.77	19.30%	―	17.62%	19.89%
BMRN	76 Outperform	$10.91B	16.82	11.62%	―	17.38%	153.58%
INCY	75 Outperform	$15.46B	18.00	24.30%	―	18.87%	1088.27%
EXEL	73 Outperform	$10.07B	17.94	29.00%	―	10.73%	81.66%
Sector *	60 Neutral	HK$18.14B	4.94	-4.00%	3.36%	10.19%	-23.62%
ASND	56 Neutral	$11.87B	―	357.68%	―	55.77%	46.81%

BioMarin Pharmaceutical Corporate Events

BioMarin Announces Resignation of Chief Accounting Officer

On August 5, 2025, BioMarin Pharmaceutical announced the resignation of Erin Burkhart, their Group Vice President and Chief Accounting Officer, effective September 2, 2025. The company will search for her successor, and in the interim, Brian Mueller, the Executive Vice President and Chief Financial Officer, will assume her responsibilities without additional compensation.

The most recent analyst rating on (BMRN) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Expands Board with New Director Appointment

On July 30, 2025, BioMarin Pharmaceutical‘s Board of Directors expanded from ten to eleven members, appointing Ian T. Clark effective August 1, 2025. Mr. Clark joins the Audit and Science and Technology Committees, receiving standard director fees and a $400,000 restricted stock unit grant. This strategic move aims to strengthen BioMarin’s governance and oversight, potentially enhancing its industry positioning and stakeholder confidence.

The most recent analyst rating on (BMRN) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Pharmaceutical Approves Equity Plan Amendment

On May 20, 2025, BioMarin Pharmaceutical Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 8,000,000. This amendment, effective immediately, was previously approved by the Compensation Committee, indicating strong internal support for expanding equity incentives. Additionally, stockholders elected ten directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation, reflecting continued confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Acquires Inozyme Pharma for $270 Million

On May 16, 2025, BioMarin Pharmaceutical Inc. announced an agreement to acquire Inozyme Pharma, Inc. for approximately $270 million. This acquisition aims to enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, a rare genetic condition. The transaction is expected to close in the third quarter of 2025, pending regulatory approval and other conditions. The acquisition is strategically significant for BioMarin, as it aligns with their commitment to advancing treatments for serious genetic conditions, potentially offering the first treatment for ENPP1 Deficiency. The first pivotal data readout for INZ-701 in children is anticipated in early 2026, with a potential launch in 2027, marking a significant step forward in addressing unmet medical needs.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.